An Interactive Annotated World Bibliography of Printed and Digital Works in the History of Medicine and the Life Sciences from Circa 2000 BCE to 2022 by Fielding H. Garrison (1870-1935), Leslie T. Morton (1907-2004), and Jeremy M. Norman (1945- ) Traditionally Known as “Garrison-Morton”

15969 entries, 13962 authors and 1940 subjects. Updated: June 12, 2024

PORTER, David L.

1 entries
  • 14112

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

New Eng. J. Med., 365, 725-733, 2011.

Carl H. June and colleagues proved that the ‘concept’ of CAR T-cell therapy developed by them, was a very promising and viable alternative in specific recalcitrant cancers. They showed that their novel in-vitro-created molecular cocktail of agents including T-cells, chimeric antigen receptors and other esoteric ingredients (T-cells engineered in the lab to target the specific CD19 in cancerous B cells delivered into the patient in a HIV lentiviral vector), met the following requirements:
1) The one patient treated had basically two severe adverse reactions: tumor lysis and lymphopenia. Both were then treatable.
2) The one patient treated had a remission still ongoing at 10 months after treatment.
3) The novel engineered cells given to the patient persisted at high levels for 6 months after therapy.

Order of authorship in the original publication: Porter, Levine, Kalos, June. Full text available from nejm.org at this link.

(Thanks to Juan Weiss for this reference and its interpretation.)



Subjects: ONCOLOGY & CANCER › Leukemia